Published in Cancer Weekly, August 1st, 2006
Scientists in South Korea conducted a study "to evaluate the efficacy and safety of concurrent chemoradiotherapy with paclitaxel and carboplatin after hysterectomy for early stage uterine cervical carcinoma with high risk factors."
"Between March 2000 and July 2002, 37 patients with stages IB-IIB uterine cervical carcinoma were treated with radical hysterectomy and bilateral pelvic lymph node dissection followed by concurrent chemoradiotherapy (POCCRT) with two courses of paclitaxel (135 mg/m2) and carboplatin (area under the time-concentration...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.